All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000039-27 | A Pivotal Phase 3 Study of MEDI-524 (Numax??), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children | 2006-05-29 | due-trials |
| Completed, but no date, and reported results | 2004-000211-26 | A comperative, placebo-controlled, doubleblind, double dummy, cross over, single center phase IIIb study between formoterol alone and the fixed combination of formoterol and budesonide on airway respo... | bad-data | |
| Reported results | 2004-000344-24 | A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-fr... | 2009-02-25 | due-trials |
| Reported results | 2004-000347-14 | A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to... | 2008-05-19 | due-trials |
| Reported results | 2004-000348-25 | GALLANT 8 - A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Thera... | 2006-03-03 | due-trials |
| Reported results | 2004-000350-24 | A 16-Week Randomized, Double-blind, Parallel-group, Multicentre, Placebo- and Active- Metformin Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy when... | 2006-07-31 | due-trials |
| Reported results | 2004-000352-16 | A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment... | 2005-06-03 | due-trials |
| Reported results | 2004-000358-21 | A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiotherapy... | 2006-06-01 | due-trials |
| Completed, but no date, and reported results | 2004-000359-41 | A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboembolic Complications... | bad-data | |
| Reported results | 2004-000379-32 | A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated... | 2007-10-31 | due-trials |
| Completed, but no date, and reported results | 2004-000383-27 | A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel S... | bad-data | |
| Reported results | 2004-000384-10 | An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious ... | 2017-12-06 | due-trials |
| Ongoing | 2004-000495-14 | A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER | not-yet-due | |
| Completed, but no date, and reported results | 2004-000566-12 | CHANT (Cerebral Hemorrhage And NXY Treatment) A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intravenous... | bad-data | |
| Reported results | 2004-000585-13 | A RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE SAFETY AND RELATIVE EFFICACY OF CAIV-T AGAINST INACTIVATED INFLUENZA VACCINE IN CHILDREN 659 MONTHS OF AGE. | 2005-08-31 | due-trials |
| Reported results | 2004-000679-32 | A comparison of the efficacy of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 microg, one inhalation twice a day plus as-needed) and conventional best standard treatment for the treat... | 2006-12-19 | due-trials |
| Reported results | 2004-000727-15 | A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive Adva... | 2014-09-04 | due-trials |
| Reported results | 2004-000750-22 | A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tabl... | 2007-08-28 | due-trials |
| Reported results | 2004-000751-42 | A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Chi... | 2008-05-11 | due-trials |
| Reported results | 2004-000795-14 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects with Severe Acute Necrotizing Pancreatitis | 2005-03-14 | due-trials |
| Reported results | 2004-000912-13 | A 6-WEEK INTERNATIONAL, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE FEASIBILITY OF SWITCHING FROM IMMEDIATE-REALESE QUETIAPINE FUMARATE SEROQUEL TM TO SUST... | 2006-03-09 | due-trials |
| Reported results | 2004-000913-21 | A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in Pati... | 2006-12-19 | due-trials |
| Reported results Terminated | 2004-000915-25 | Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenance T... | 2007-06-05 | due-trials |
| Completed, but no date, and reported results | 2004-001107-36 | A comparison of Symbicort Single inhaler Therapy (Symbicort Turbohaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolesce... | bad-data | |
| Reported results | 2004-001144-71 | A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patien... | 2007-03-14 | due-trials |
| Reported results | 2004-001168-28 | A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5μg bid and 2x80/4.5 μg bid compared to Formoterol TBH 2x4.5μg bid ... | 2007-11-30 | due-trials |
| Reported results | 2004-001183-41 | A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budesoni... | 2007-01-03 | due-trials |
| Completed, but no date, and reported results | 2004-001724-20 | A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μ... | bad-data | |
| Trial is partly outside EEC, and reported results | 2004-002370-39 | A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease GER... | bad-data | |
| Listed as ongoing, but also has a completion date | 2004-002371-16 | A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE III STUDYCOMPARING THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEX?) 500 MG WITH FULVESTRANT (FASLODEX?) 250 MG IN POSTMENOPAUSAL ... | 2014-07-30 | bad-data |
| Reported results | 2004-002549-11 | An Open, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar therapy 1 mg in patients with Type 2 Diabetes Mellitus. (Protocol Amendment Nr.1, dat... | 2007-02-28 | due-trials |
| Reported results | 2004-002550-56 | A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects,... | 2007-12-16 | due-trials |
| Reported results | 2004-002662-38 | A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARCINO... | 2007-03-16 | due-trials |
| Reported results | 2004-002746-35 | The "EXTEND" study: A randomized, double-blind, parallel-group, phase IIIb, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prevent... | 2006-08-29 | due-trials |
| Reported results | 2004-002943-28 | A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic ... | 2007-07-19 | due-trials |
| Reported results | 2004-003617-16 | A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg whe... | 2007-07-09 | due-trials |
| Not reported | 2004-003657-99 | A double-blind, randomised, placebo controlled study to evaluate the safety and efficacy of A-60444 in adults with RSV infection following stem cell transplantation | 2006-07-24 | due-trials |
| Reported results | 2004-003826-92 | "A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by day... | 2006-02-27 | due-trials |
| Reported results | 2004-003840-22 | A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients with T... | 2007-02-06 | due-trials |
| Reported results | 2004-004042-41 | A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/... | 2007-10-26 | due-trials |
| Reported results | 2004-004094-28 | A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL Ch... | 2008-10-01 | due-trials |
| Reported results | 2004-004206-25 | A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAPY-N... | 2016-04-24 | due-trials |
| Reported results | 2004-004229-93 | Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment | 2017-10-02 | due-trials |
| Reported results | 2004-004264-75 | A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with ... | 2008-09-16 | due-trials |
| Reported results | 2004-004374-90 | A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered as Monotherapy to... | 2007-02-09 | due-trials |
| Reported results | 2004-004681-33 | An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg... | 2007-06-26 | due-trials |
| Reported results | 2004-004803-39 | SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY... | 2006-10-13 | due-trials |
| Reported results | 2004-004905-11 | Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus te... | 2006-10-27 | due-trials |
| Completed, but no date Terminated | 2004-004907-39 | A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo in p... | bad-data | |
| Ongoing | 2004-004908-21 | A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo in p... | not-yet-due | |
| Reported results | 2004-004909-16 | An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg... | 2007-05-31 | due-trials |
| Completed, but no date | 2004-005093-24 | Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment | bad-data | |
| Reported results | 2004-005122-45 | RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study | 2006-09-13 | due-trials |
| Reported results | 2004-005169-39 | A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d. | 2007-02-22 | due-trials |
| Reported results | 2004-005243-97 | A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar Therapy in Patients with Type 2 Diabetes Mellit... | 2007-02-16 | due-trials |
| Reported results | 2005-000204-13 | A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to pati... | 2006-05-09 | due-trials |
| Reported results | 2005-000211-99 | Acutely Manic Patients Insufficiently Responding After 2 Weeks Continued Quetiapine Monotherapy: Continued Quetiapine Versus Sodium Valproate Add-on. | 2006-10-05 | due-trials |
| Reported results | 2005-000258-64 | SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cogni... | 2008-02-13 | due-trials |
| Reported results | 2005-000372-41 | Real life effectiveness in asthma of Symbicort® Single Inhaler Therapy (RELEASE) | 2007-01-31 | due-trials |
| Reported results | 2005-000458-57 | A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other P... | 2007-02-20 | due-trials |
| Reported results | 2005-000532-25 | A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolesc... | 2008-06-06 | due-trials |
| Reported results | 2005-001090-10 | A randomised, double blind, double dummy, multicentre phase III study comparing the efficacy of budesonide/formoterol (Symbicort® forte Turbuhaler®) and oral prednisolone + formoterol (Oxis® Turbuhale... | 2007-09-07 | due-trials |
| Reported results | 2005-001373-97 | A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatmen... | 2007-02-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-001671-35 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ... | 2008-06-26 | bad-data |
| Reported results | 2005-001737-15 | An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant... | 2007-11-01 | due-trials |
| Reported results | 2005-002319-26 | Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study | 2007-05-25 | due-trials |
| Reported results | 2005-002441-39 | A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to asse... | 2008-01-04 | due-trials |
| Reported results | 2005-002508-41 | A Randomised, Double-Blind, 52-week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretio... | 2009-06-29 | due-trials |
| Reported results | 2005-002510-38 | A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretion ... | 2009-03-04 | due-trials |
| Reported results | 2005-002584-90 | A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Sputum... | 2006-04-06 | due-trials |
| Completed, but no date, and reported results | 2005-002805-21 | A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic... | bad-data | |
| Reported results | 2005-002868-28 | A Randomised, Open-Label, Parallel-Group, Multi-centre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as First Line Horm... | 2017-01-13 | due-trials |
| Reported results | 2005-002889-11 | An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvastati... | 2007-02-15 | due-trials |
| Reported results | 2005-002892-34 | Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome | 2007-11-22 | due-trials |
| Reported results | 2005-003251-13 | Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study | 2007-08-30 | due-trials |
| Reported results | 2005-003440-66 | A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab i... | 2015-08-19 | due-trials |
| Reported results | 2005-003441-13 | A Two-part, Open-label, Multi-centre, Phase II Study in Patients with Advanced Solid Tumours, Consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmacoki... | 2008-09-03 | due-trials |
| Reported results | 2005-003442-33 | A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Solid ... | 2011-04-26 | due-trials |
| Reported results | 2005-003443-31 | A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination wi... | 2009-10-30 | due-trials |
| Reported results | 2005-003591-38 | A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with Arimidex vs. Arimidex alone in patients with hormone sensitive (ER+ve and... | 2006-08-30 | due-trials |
| Reported results | 2005-003592-20 | A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with docetaxel (Taxotere) vs docetaxel alone as 2nd line treatment for advance... | 2009-01-02 | due-trials |
| Reported results | 2005-003593-16 | A phase II, double-blind, placebo-controleed, randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hor... | 2008-09-16 | due-trials |
| Reported results | 2005-003745-14 | A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monotherap... | 2007-09-12 | due-trials |
| Reported results | 2005-004001-29 | An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Po... | 2009-11-18 | due-trials |
| Reported results Terminated | 2005-004032-48 | A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metfo... | 2007-01-09 | due-trials |
| Reported results | 2005-004110-32 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with M... | 2006-11-16 | due-trials |
| Reported results | 2005-004247-54 | A Randomised, Double-blind, Parallel-group, Multicentre, Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 250 mg, Fulvestrant (FASLODEX™) 250 mg (plus 250 mg Loading... | 2019-03-13 | due-trials |
| Reported results | 2005-004543-57 | A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole NexiumTR 40 mg twice daily or 40 mg onc... | 2008-05-21 | due-trials |
| Reported results | 2005-004548-30 | A Phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients with ... | 2015-06-26 | due-trials |
| Reported results | 2005-004749-32 | A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel TAXOTERE in Combination with ZD6474 ZACTIMA versus Docetaxel TAXOTERE in combination with Placebo ... | 2013-02-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2005-004893-26 | An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of FASLODEX fulvestrant in Girls with Progressive Precocious Puberty Associated with McCune Albright Syndr... | 2023-07-20 | bad-data |
| Reported results | 2005-005052-40 | A Multi-Centre, Double-Blind, Randomised, Parallel Group, Placebo-Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) a... | 2007-07-10 | due-trials |
| Reported results | 2005-005053-22 | A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination with an ... | 2007-05-23 | due-trials |
| Reported results | 2005-005054-46 | An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR™ )... | 2007-07-10 | due-trials |
| Reported results | 2005-005055-18 | A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monotherap... | 2007-10-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2005-005077-29 | An International, Phase II, Randomized, Double-Blinded, Placebo- Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 ZACTIMA versus Placebo in Subjects with Unresectable Locally Advan... | 2015-11-23 | bad-data |
| Reported results | 2005-005715-22 | A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marro... | 2009-01-15 | due-trials |
| Reported results | 2005-005717-38 | An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intoler... | 2009-12-21 | due-trials |
| Reported results | 2005-005718-19 | A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazid... | 2007-10-24 | due-trials |
| Reported results | 2005-005974-64 | Comparación del tratamiento con un único inhalador de Symbicort (Symbicort Turbuhaler 160/4,5 mg, 1 inhalación 2 veces/día como dosis de mantenimiento, y a demanda para el alivio de los síntomas, SM... | 2008-10-15 | due-trials |
| Reported results | 2006-000257-22 | A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton pu... | 2007-06-11 | due-trials |
| Reported results | 2006-000259-16 | A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (Stage... | 2016-11-15 | due-trials |
| Reported results | 2006-000320-14 | Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi... | 2012-02-01 | due-trials |
| Reported results Terminated | 2006-000418-20 | A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate ch... | 2006-12-15 | due-trials |
| Reported results | 2006-000574-69 | Development of an algorithm for identification of responders to short term treatment with esomeprazol (Nexium) in primary care. | 2007-03-12 | due-trials |
| Reported results | 2006-000658-27 | A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coro... | 2009-05-20 | due-trials |
| Reported results | 2006-000954-31 | Centralised Pan-European Survey on the Undertreatment of Hyperchlesterolemia | 2007-03-22 | due-trials |
| Ongoing | 2006-000978-68 | Treatment of systemic effects in patients with COPD | not-yet-due | |
| Reported results | 2006-001193-25 | A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma. | 2007-08-28 | due-trials |
| Reported results | 2006-001194-14 | A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of AZD2171 when added to 5 fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) with... | 2016-08-17 | due-trials |
| Reported results | 2006-001195-21 | A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Tr... | 2008-05-22 | due-trials |
| Reported results | 2006-001196-38 | A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono-Therapy in the ... | 2008-02-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2006-001197-24 | A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or M... | 2007-09-18 | bad-data |
| Reported results | 2006-001259-36 | A randomised, parallel group, single blind, multicentre, 9-month, phase IV study in a primary care setting, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guided ... | 2009-01-16 | due-trials |
| Reported results | 2006-001316-76 | A randomized, open, parallel-group, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months mainten... | 2007-10-22 | due-trials |
| Reported results | 2006-001354-28 | A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Not... | 2014-05-30 | due-trials |
| Reported results | 2006-001456-12 | A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanoma | 2013-07-24 | due-trials |
| Reported results | 2006-001457-10 | A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda) in Patients with Colorectal Cancer who have Failed One Or Two Prior Chemotherapeutic Regimens. | 2008-07-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-002001-31 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of esomeprazole once daily for the treatment of gastroesophageal reflux disease (GERD) in neonatal patients, in... | 2009-04-19 | bad-data |
| Reported results | 2006-002384-12 | A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care i... | 2014-11-30 | due-trials |
| Reported results | 2006-002412-10 | A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™50/500... | 2007-12-18 | due-trials |
| Reported results | 2006-002455-33 | A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Car... | 2016-10-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-002616-96 | A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomized,... | 2008-06-04 | bad-data |
| Reported results | 2006-002867-19 | Evaluation de l’efficacité de 3 stratégies de prise en charge au long cours des symptômes de reflux gastro-oesophagien en médecine générale : étude multicentrique, randomisée, en ouvert, réalisée en g... | 2008-10-01 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-003286-14 | A phase IV, 6-week, randomised, double-blind, multicentre, parallel group, comparative study to evaluate the efficacy of rosuvastatin 5 mg and atorvastatin 10 mg in UK Asian subjects with primary hype... | bad-data | |
| Reported results Terminated | 2006-003519-33 | RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffective ... | 2007-09-19 | due-trials |
| Reported results | 2006-003541-16 | A randomized, double-blind, placebo controlled, multi-centre, phase IIA study to assess the effect on GERD symptoms, pharmacokinetics, safety and tolerability of four weeks treatment with AZD3355 65 m... | 2007-07-10 | due-trials |
| Listed as ongoing, but also has a completion date | 2006-003695-35 | A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 ZACTIMA in Combination with Pemetrexed Alimta versus Pemetrexed alone in ... | 2009-10-16 | bad-data |
| Reported results | 2006-003963-30 | A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochl... | 2008-02-04 | due-trials |
| Reported results | 2006-004501-25 | A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (T... | 2008-05-12 | due-trials |
| Not reported | 2006-004783-31 | A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses ... | 2007-08-27 | due-trials |
| Reported results | 2006-005022-23 | A Phase II, Double-Blind, Placebo Controlled, Randomised Study To Assess The Efficacy And Safety Of 2 Doses Of ZACTIMA (ZD6474) In Combination With FOLFOX vs FOLFOX Alone For The Treatment Of Colorect... | 2016-11-11 | due-trials |
| Reported results | 2006-005023-42 | A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of color... | 2008-04-21 | due-trials |
| Reported results | 2006-005073-22 | A randomized, double-blind, parallel-group study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in patients on continous low-dos... | 2008-09-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-005212-27 | A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesopha... | 2008-09-23 | bad-data |
| Reported results | 2006-005437-38 | A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of St... | 2008-07-08 | due-trials |
| Completed, but no date, and reported results | 2006-005677-22 | A follow-up programme for patients using Symbicort® Turbuhaler® maintenance and reliever therapy in normal clinical practice | bad-data | |
| Reported results | 2006-005746-36 | A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitab... | 2008-04-30 | due-trials |
| Reported results Terminated | 2006-006426-26 | FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Convent... | 2008-04-23 | due-trials |
| Reported results | 2006-006427-39 | The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic Symptoms | 2008-10-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-006458-91 | A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated ... | 2022-12-21 | bad-data |
| Reported results | 2006-006459-10 | A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated ... | 2017-07-20 | due-trials |
| Reported results | 2006-006512-30 | A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5... | 2009-01-16 | due-trials |
| Reported results | 2006-006519-60 | A multi-centre, randomised, double-blind, cross-over design study to evaluate efficacy on exercise tolerance of budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 μg one inhalation twice daily compar... | 2008-08-22 | due-trials |
| Reported results | 2006-006697-15 | Evaluation de l'efficacité et de la tolérance de rosuvastatine 5 mg versus pravastatine 40 mg et atorvastatine 10 mg chez des patients hypercholestérolémiques de type IIa et IIb | 2008-10-01 | due-trials |
| Reported results | 2006-006796-21 | A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of... | 2008-07-15 | due-trials |
| Reported results | 2006-006946-32 | A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Backgrou... | 2009-03-25 | due-trials |
| Completed, but no date Terminated | 2007-000328-42 | A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers ... | bad-data | |
| Reported results | 2007-000383-24 | A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib wi... | 2016-09-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-000628-41 | A Phase I, Randomized, Open-Label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 Years Old, Inclusive | 2009-11-12 | bad-data |
| Reported results | 2007-000835-24 | A Multi-centre, Double-blind, Double-Dummy, Placebo-controlled, Parallel Group, Randomised, Phase IIb Proof of Concept Study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment i... | 2008-08-27 | due-trials |
| Reported results | 2007-001337-34 | A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/form... | 2008-11-12 | due-trials |
| Reported results | 2007-001420-12 | A Randomised, Double-Blind (with Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Sign... | 2009-05-14 | due-trials |
| Reported results | 2007-001545-17 | An Open-Label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: A Long Term Study | 2009-09-09 | due-trials |
| Ongoing, reported early | 2007-001722-27 | Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk fact... | not-yet-due | |
| Reported results | 2007-001723-36 | A controlled, randomized, parallel, multi-centre, feasibility study of the oral direct thrombin inhibitor AZD0837, given as extended-release formulation, in the prevention of stroke and systemic embol... | 2008-11-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-001890-27 | A Randomised, double blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with locally advanced or metastatic papillary or follicular Thyroi... | 2008-09-22 | bad-data |
| Reported results | 2007-001891-35 | A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic... | 2011-07-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-002070-61 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ... | 2008-06-26 | bad-data |
| Reported results Terminated | 2007-002090-31 | A double-blind, placebo-controlled parallel-group study to assess the efficacy, safety, and tolerability of CAT-354 | 2008-10-10 | due-trials |
| Reported results | 2007-002722-29 | A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations Symbicort (budesonide/formoterol) HFA pMDI 40/2.25ug twice daily, with and witho... | 2008-03-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-002734-11 | A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 μg twice daily comp... | 2008-04-17 | bad-data |
| Reported results | 2007-002810-20 | A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and Siv... | 2008-12-12 | due-trials |
| Reported results | 2007-003056-12 | A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WITH A... | 2012-09-30 | due-trials |
| Reported results | 2007-003224-38 | A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer P... | 2011-05-01 | due-trials |
| Reported results | 2007-003227-20 | A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or... | 2011-08-01 | due-trials |
| Reported results | 2007-003228-39 | A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastat... | 2011-07-01 | due-trials |
| Reported results Terminated | 2007-003455-36 | A Multi-centre, Double-blind, Randomised, Placebo-controlled, Single-dose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of... | 2008-07-09 | due-trials |
| Reported results | 2007-003633-16 | A RANDOMIZED PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF VANDETANIB (ZD6474, ZACTIMATM) VERSUS VINORELBINE IN PATIENTS WITH INOPERABLE OR RELAPSED MALIGNANT MESOTHELIOMA | 2009-08-26 | due-trials |
| Reported results | 2007-003962-16 | A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic Obst... | 2008-08-06 | due-trials |
| Reported results | 2007-003998-55 | A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin i... | 2010-09-24 | due-trials |
| Reported results | 2007-004000-13 | A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effect of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as m... | 2011-08-10 | due-trials |
| Completed, but no date, and reported results | 2007-004246-32 | Comparison of Quetiapine Extended-Release (Seroquel XR ) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose... | bad-data | |
| Completed, but no date, and reported results | 2007-004521-22 | Phase II, Randomised, double-blind, two-arm, parallel study of Vandetanib (ZACTIMA , ZD6474) plus Gemcitabine (Gemzar ) or Gemcitabine plus Placebo as first line treatment of advanced (stage IIIB or I... | bad-data | |
| Other | 2007-004584-22 | A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Sputum... | not-yet-due | |
| Reported results | 2007-004740-79 | A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL XR) or Oral Risperidone at Flexible Dose in... | 2010-02-09 | due-trials |
| Reported results | 2007-004951-12 | A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin compared with Placebo in Adult Patients with Type... | 2010-04-09 | due-trials |
| Reported results | 2007-005220-33 | A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozi... | 2013-02-25 | due-trials |
| Reported results | 2007-005325-30 | A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy | 2012-02-21 | due-trials |
| Completed, but no date, and reported results | 2007-005773-63 | A Pilot Study of Three-Weeks, Randomized, Prospective, Open Comparison in Schizophrenic In-patients Treated with Quetiapine Prolong or Oral Risperidone at Flexible Dose | bad-data | |
| Reported results | 2007-005931-27 | A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylur... | 2010-06-28 | due-trials |
| Reported results | 2007-005999-13 | A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease | 2012-08-20 | due-trials |
| Reported results | 2007-006095-11 | An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin... | 2009-04-07 | due-trials |
| Reported results | 2007-006249-42 | A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma | 2009-05-19 | due-trials |
| Reported results | 2007-006250-25 | A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN™) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy ... | 2008-09-18 | due-trials |
| Exempt, with results | 2007-006647-45 | A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary Mye... | 2014-08-25 | not-yet-due |
| Reported results | 2007-007058-79 | A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship between QTcF Interval at First Dose (Loading Dose) and at Steady State after Tr... | 2008-09-30 | due-trials |
| Reported results Terminated | 2007-007127-40 | CARE II - Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre phase IV study | 2008-09-30 | due-trials |
| Reported results | 2007-007539-14 | A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered... | 2009-05-19 | due-trials |
| Reported results | 2007-007540-10 | A 24-week international, randomized, parallel-group, double-blind, placebo-controlled Phase III study with a 24-week extension period to evaluate the efficacy and safety of dapagliflozin therapy when ... | 2011-03-14 | due-trials |
| Reported results | 2007-007622-22 | A Phase II Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposom... | 2018-09-19 | due-trials |
| Listed as ongoing, but also has a completion date | 2007-007623-40 | A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell... | 2010-09-24 | bad-data |
| Exempt | 2008-000062-24 | Ensayo fase I/II, abierto, multicéntrico, de AZD2281 oral en combinación con Cisplatino, para valorar la seguridad y tolerabilidad en pacientes con tumores sólidos avanzados, y para valorar la eficaci... | not-yet-due | |
| Reported results | 2008-000311-15 | A Double-Blind, Placebo-Controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients with Moderate to S... | 2009-07-20 | due-trials |
| Reported results | 2008-000340-13 | A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Dis... | 2009-03-03 | due-trials |
| Reported results | 2008-000579-12 | A randomised, double-blind, parallel-group, multicentre, phase ii study to evaluate the safety and pharmacological activity of the combination of Vandetanib (100 or 300 mg/daily or placebo) with Fulve... | 2013-09-28 | due-trials |
| Reported results | 2008-000724-12 | A 2-week, randomised, double-blind, placebo-controlled, parallel group study to assess the tolerability and pharmacokinetics of orally administered AZD9668 in patients with COPD | 2008-10-29 | due-trials |
| Reported results | 2008-000744-13 | An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study | 2013-08-21 | due-trials |
| Reported results | 2008-000753-35 | A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Bronchiectasis | 2009-04-20 | due-trials |
| Reported results | 2008-000907-27 | A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Uroth... | 2010-02-09 | due-trials |
| Reported results | 2008-000908-91 | A randomised, 6-week, multicentre, open-label, rater-blinded parallel group study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatmen... | 2009-08-17 | due-trials |
| Ongoing, reported early | 2008-000989-23 | A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED CP-675,206 IN OTHER PROTOCOLS | not-yet-due | |
| Reported results | 2008-001254-41 | A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an iv infusion on left ventricular performance in patients with left ventric... | 2009-08-19 | due-trials |
| Reported results | 2008-001530-27 | A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis | 2009-08-04 | due-trials |
| Reported results | 2008-001724-32 | A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to for... | 2009-02-04 | due-trials |
| Reported results | 2008-002151-25 | A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Table... | 2009-08-20 | due-trials |
| Reported results | 2008-002230-30 | A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe CO... | 2009-07-21 | due-trials |
| Reported results | 2008-002332-15 | A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect short-... | 2009-05-07 | due-trials |
| Exempt, with results | 2008-002606-18 | A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Adva... | 2010-11-29 | not-yet-due |
| Exempt, with results | 2008-002608-25 | A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Tripl... | 2018-02-19 | not-yet-due |
| Completed, but no date, and reported results | 2008-002649-22 | Efectividad de quetiapina de liberación prolongada vs sertralina como terapia co-adyuvante al tratamiento eutimizante previo en la depresión bipolar aguda: un estudio piloto | bad-data | |
| Exempt, with results | 2008-002651-24 | A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated I... | 2012-08-23 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2008-003439-18 | Estudio en fase II aleatorizado, doble ciego y multicéntrico, para evaluar la eficacia de AZD2281 en el tratamiento de pacientes con cáncer de ovario seroso sensible al platino tras el tratamiento co... | 2023-10-12 | bad-data |
| Listed as ongoing, but also has a completion date | 2008-003698-42 | A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin fo... | 2013-08-13 | bad-data |
| Reported results | 2008-004699-34 | A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis. | 2009-04-28 | due-trials |
| Reported results | 2008-004913-93 | A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Combina... | 2011-12-22 | due-trials |
| Not reported | 2008-004916-12 | A 24-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin ... | 2009-05-08 | due-trials |
| Reported results | 2008-005305-19 | A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Clopi... | 2009-04-20 | due-trials |
| Exempt, with results | 2008-005557-38 | Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study | 2010-11-29 | not-yet-due |
| Reported results | 2008-006068-12 | A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Canc... | 2011-07-13 | due-trials |
| Reported results | 2008-006323-31 | A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line Patients with... | 2011-09-22 | due-trials |
| Reported results | 2008-006344-19 | A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Pos... | 2012-10-02 | due-trials |
| Ongoing | 2008-006742-26 | Evaluation Study of a New Management Strategy for Gastroesophageal Reflux Disease (GERD) | not-yet-due | |
| Reported results | 2008-006869-86 | A comparison of Symbicort® Maintenance and Reliever Therapy (Symbicort Turbuhaler® 160/4.5 mg, one inhalation bid plus as-needed) and Symbicort Turbuhaler 160/4.5 mg, one inhalation bid plus terbutali... | 2011-02-23 | due-trials |
| Reported results | 2008-007190-20 | An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) in A... | 2010-11-17 | due-trials |
| Reported results Terminated | 2008-007420-26 | A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensiti... | 2011-01-12 | due-trials |
| Reported results | 2008-007797-37 | A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three diffe... | 2009-07-14 | due-trials |
| Reported results | 2008-007844-33 | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Fully Human Monoclonal Antibody Directed Against Interleukin... | 2010-08-03 | due-trials |
| Reported results Terminated | 2009-009862-15 | A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation | 2009-11-20 | due-trials |
| Reported results | 2009-010114-30 | A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in c... | 2012-04-26 | due-trials |
| Reported results | 2009-010551-26 | A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Sele... | 2015-02-05 | due-trials |
| Reported results | 2009-010864-40 | A double-blind, double-dummy, placebo-controlled, randomised, multi-centre, 5-way cross-over, single-dose study to investigate the local and systemic effects of inhaled AZD9164 compared to tiotropium ... | 2009-11-26 | due-trials |
| Reported results | 2009-011044-20 | A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Comp... | 2009-07-01 | due-trials |
| Reported results | 2009-011148-21 | A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose ... | 2010-08-05 | due-trials |
| Reported results | 2009-011265-82 | A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formo... | 2010-03-19 | due-trials |
| Not reported | 2009-012094-35 | A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in... | 2009-12-18 | due-trials |
| Reported results | 2009-012541-33 | A randomised, placebo-controlled, double-blind (double-dummy technique), crossover, multi-centre study, to evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treate... | 2010-05-19 | due-trials |
| Reported results | 2009-012612-41 | A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, with an Optional 2-Month Extension to Evaluate Efficacy, Safety and Tolerability of AZD1656 as ... | 2011-02-01 | due-trials |
| Reported results | 2009-012775-10 | A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patie... | 2010-12-03 | due-trials |
| Reported results | 2009-012805-20 | A randomised, double blind, placebo controlled, parallel-group study with use of budesonide/formoterol “as-needed”, or terbutaline “as-needed” or regular use of budesonide + terbutaline “as-needed”, i... | 2010-07-19 | due-trials |
| Reported results | 2009-012806-37 | A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin... | 2011-09-26 | due-trials |
| Reported results | 2009-012816-41 | A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients with Typ... | 2012-06-14 | due-trials |
| Reported results Terminated | 2009-012934-63 | A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopa... | 2013-01-31 | due-trials |
| Reported results | 2009-012935-13 | A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in dos... | 2010-07-08 | due-trials |
| Exempt, with results Terminated | 2009-013110-27 | A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for Major Depressive Dis... | 2011-03-17 | not-yet-due |
| Trial is outside EEC, and reported results | 2009-013326-17 | A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children | bad-data | |
| Reported results | 2009-013705-34 | A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once... | 2011-12-05 | due-trials |
| Reported results | 2009-014586-75 | A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subjects... | 2010-08-18 | due-trials |
| Reported results | 2009-014594-40 | A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668 Administered Orally Twice Daily on Structural Changes in the... | 2010-11-17 | due-trials |
| Reported results | 2009-014735-20 | A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis | 2012-07-27 | due-trials |
| Reported results | 2009-015168-32 | A Multicentre, Randomised, Double Blind, Placebo controlled Phase IIb Study to compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of CytoFabTM (AZD9773) in Adult Patients ... | 2012-05-25 | due-trials |
| Reported results | 2009-015525-37 | Safety, Tolerability and Pharmacokinetics of 3 Dose regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo controlled, Parallel group Ph... | 2010-07-29 | due-trials |
| Ongoing | 2009-015970-36 | A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin... | not-yet-due | |
| Exempt, with results | 2009-016378-34 | An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies | 2019-03-06 | not-yet-due |
| Completed, but no date, and reported results | 2009-016468-35 | A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in pat... | bad-data | |
| Trial is partly outside EEC, and reported results | 2009-016492-29 | An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia | 2013-02-12 | bad-data |
| Reported results | 2009-016791-71 | A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once da... | 2012-12-06 | due-trials |
| Reported results | 2009-017061-28 | A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once dai... | 2013-01-18 | due-trials |
| Reported results | 2009-017242-30 | A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicyl... | 2014-12-03 | due-trials |
| Reported results | 2009-017358-10 | SAVOR Evaluación de saxagliptina a partir de los resultados vasculares registrados en pacientes con diabetes mellitus Ensayo clínico fase IV, multicéntrico, aleatorizado, doble ciego, controlado con p... | 2013-05-16 | due-trials |
| Not reported | 2009-018157-23 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Mu... | 2010-12-16 | due-trials |
| Reported results | 2010-018273-38 | A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose o... | 2011-03-01 | due-trials |
| Reported results | 2010-018315-15 | A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 to ... | 2013-04-05 | due-trials |
| Reported results | 2010-018316-32 | A Phase 2, randomized, blinded, 5-period cross-over, placebo and activecontrolled, multicenter, dose-finding study of single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pMDI ... | 2012-10-16 | due-trials |
| Completed, but no date | 2010-018361-33 | A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Pati... | bad-data | |
| Completed, but no date, and reported results | 2010-018608-98 | A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers | bad-data | |
| Reported results | 2010-018614-70 | An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA?) as First line Treatment in Caucasian Patients, who have Epidermal Growt... | 2016-06-06 | due-trials |
| Reported results | 2010-019203-31 | A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine He... | 2014-04-24 | due-trials |
| Reported results | 2010-019428-30 | A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb tudy to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in Subjects with ... | 2011-06-14 | due-trials |
| Reported results | 2010-019511-37 | A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients w... | 2011-08-25 | due-trials |
| Reported results | 2010-019785-90 | A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumati... | 2012-04-03 | due-trials |
| Reported results | 2010-019925-33 | A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Pat... | 2011-09-27 | due-trials |
| Reported results | 2010-020126-17 | A Phase 2b, dose-ranging study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma | 2013-08-15 | due-trials |
| Reported results | 2010-020127-52 | A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophilia | 2013-07-11 | due-trials |
| Reported results | 2010-020140-36 | A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant... | 2012-01-30 | due-trials |
| Reported results | 2010-020141-26 | A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Segmen... | 2011-07-28 | due-trials |
| Reported results | 2010-020407-73 | A double-blind, placebo-controlled, randomised, parallel-group, phase-II, multi-centre study to assess the efficacy, safety and tolerability of 4 twice daily doses and 2 once daily doses of AZD1981 gi... | 2012-02-16 | due-trials |
| Reported results | 2010-020579-21 | A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed twice D... | 2011-08-03 | due-trials |
| Reported results | 2010-020743-12 | A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respon... | 2012-11-26 | due-trials |
| Reported results | 2010-020744-35 | A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respo... | 2013-03-19 | due-trials |
| Reported results | 2010-020745-27 | A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response ... | 2013-02-11 | due-trials |
| Reported results | 2010-020747-13 | A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally t... | 2012-02-10 | due-trials |
| Exempt, with results Terminated | 2010-020820-23 | A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | not-yet-due | |
| Reported results | 2010-020891-43 | A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to Sev... | 2011-03-08 | due-trials |
| Reported results | 2010-020892-22 | A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis | 2013-06-28 | due-trials |
| Reported results | 2010-020932-20 | A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure | 2012-11-30 | due-trials |
| Reported results | 2010-021217-23 | A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate to... | 2011-03-22 | due-trials |
| Reported results | 2010-021220-10 | A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patien... | 2014-10-21 | due-trials |
| Reported results Terminated | 2010-021472-28 | A Phase II Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients with Bronchiectasis. | 2012-02-10 | due-trials |
| Exempt, with results | 2010-021520-10 | An open, single centre, phase I study in male adolescents with asthma, aged 12 to 17 years, to assess pharmacokinetics of orally administered AZD1981 tablets 100mg twice daily for 6½ days | 2011-02-02 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2010-022278-15 | A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confirmed... | 2024-08-12 | bad-data |
| Reported results | 2010-023377-19 | A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Third... | 2015-02-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2010-023428-26 | A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medulla... | 2016-05-13 | bad-data |
| Reported results | 2010-023692-26 | (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Mono... | 2013-07-17 | due-trials |
| Reported results Terminated | 2010-023816-15 | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as... | 2012-03-20 | due-trials |
| Reported results | 2010-023854-35 | A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell ... | 2013-09-04 | due-trials |
| Reported results | 2010-024069-30 | A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Studio di fase IIb, per valutare l'efficacia e la sicurezza di Sifali... | 2014-08-20 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-024137-22 | A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant ... | bad-data | |
| Reported results | 2011-000133-37 | A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa study to Evaluate the Pharmacokinetics and Pharmacodynamics of different Dry Powder I... | 2012-02-27 | due-trials |
| Reported results | 2011-000198-29 | A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC) | 2019-06-28 | due-trials |
| Reported results | 2011-000214-19 | A 30 day international, randomized, parallel-group, double-blind, placebo-controlled phase IV study to evaluate efficacy and safety of pre-hospital vs. in-hospital initiation of ticagrelor therapy in ... | 2013-11-14 | due-trials |
| Reported results | 2011-001360-21 | A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma | 2014-02-22 | due-trials |
| Reported results | 2011-001716-59 | A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing ... | 2011-12-22 | due-trials |
| Reported results | 2011-001985-16 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain. | 2012-09-20 | due-trials |
| Reported results | 2011-001986-41 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) | 2012-09-21 | due-trials |
| Reported results | 2011-001987-24 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) | 2012-08-16 | due-trials |
| Reported results | 2011-002187-24 | A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) | 2012-09-13 | due-trials |
| Reported results | 2011-002231-26 | A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study with a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg once daily... | 2013-08-12 | due-trials |
| Reported results | 2011-002523-17 | A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy, Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose... | 2012-08-27 | due-trials |
| Reported results | 2011-002563-23 | A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease | 2014-02-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-002565-38 | A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL Studio in aperto randomizzato di fase 2 su MEDI-551 in adulti con LDGCB recidivante o refrattario | 2016-07-17 | bad-data |
| Reported results | 2011-002566-21 | A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL Studio in aperto di fase 2 su MEDI-551 e bendamustina rispetto a rit... | 2016-01-08 | due-trials |
| Reported results | 2011-002790-28 | A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®,... | 2015-10-13 | due-trials |
| Reported results | 2011-003742-40 | A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive | 2014-02-13 | due-trials |
| Reported results | 2011-003743-22 | A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive Studio non compara... | 2014-09-10 | due-trials |
| Reported results | 2011-003893-97 | A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ104) Plus Metronida... | 2014-04-07 | due-trials |
| Reported results | 2011-003895-35 | A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ104) Plus Metronid... | 2014-04-07 | due-trials |
| Reported results | 2011-004013-16 | A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600mg every 8 hours) Versus Vancomycin Plus Aztreonam in the Treatme... | 2015-01-02 | due-trials |
| Reported results | 2011-004296-36 | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | 2015-04-08 | due-trials |
| Reported results | 2011-004616-36 | A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke... | 2016-09-27 | due-trials |
| Reported results | 2011-004641-41 | A randomised, double-blind, placebo-controlled, multi-centre, 6-way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 compar... | 2012-10-23 | due-trials |
| Reported results | 2011-004690-87 | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of... | 2013-08-23 | due-trials |
| Listed as ongoing, but also has a completion date | 2011-004701-24 | An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thy... | 2016-06-29 | bad-data |
| Reported results | 2011-004803-19 | A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positr... | 2013-01-09 | due-trials |
| Reported results | 2011-004812-40 | A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody dire... | 2013-06-24 | due-trials |
| Reported results | 2011-004942-16 | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy ... | 2019-11-20 | due-trials |
| Reported results | 2011-005157-31 | A phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as treatment re-challenge in Patients, who have Epidermal Gro... | 2015-07-31 | due-trials |
| Reported results Terminated | 2011-005194-23 | A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Pat... | 2012-11-08 | due-trials |
| Reported results | 2011-005389-39 | A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily ... | 2013-06-07 | due-trials |
| Reported results | 2011-005503-33 | A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Tralokinumab in Adolescents with Asthma Otwarte badanie fazy pierwszej w celu oceny farmakokinetyki (PK) tralokinumabu u nastolatków ... | 2013-01-09 | due-trials |
| Reported results | 2011-005634-19 | A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects with Moderate-to-Severe Rheumatoid Arthritis. | 2014-01-23 | due-trials |
| Reported results | 2011-005648-93 | An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis | 2016-12-30 | due-trials |
| Reported results | 2011-005649-10 | A Phase 2 Exploratory Study of Mavrilimumab versus Anti tumor Necrosis Factor in Subjects with Rheumatoid Arthritis | 2015-02-06 | due-trials |
| Reported results | 2011-005721-43 | A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ1... | 2014-08-17 | due-trials |
| Reported results | 2011-005722-21 | A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CA... | 2014-09-22 | due-trials |
| Reported results | 2011-006070-73 | A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Art... | 2013-01-15 | due-trials |
| Exempt, with results | 2011-006312-31 | A Phase I/II, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD536... | 2022-10-03 | not-yet-due |
| Reported results | 2011-006323-37 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination ... | 2015-01-12 | due-trials |
| Reported results | 2011-006324-20 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Me... | 2015-02-19 | due-trials |
| Ongoing | 2011-006326-24 | A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Tr... | not-yet-due | |
| Reported results | 2012-000726-21 | An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathoge... | 2014-10-29 | due-trials |
| Trial is outside EEC, and reported results | 2012-000825-33 | A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States | bad-data | |
| Trial is outside EEC, and reported results | 2012-001136-61 | A Phase III, Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GE... | bad-data | |
| Trial is outside EEC, and reported results | 2012-001155-39 | Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia | bad-data | |
| Trial is outside EEC, and reported results | 2012-001156-19 | A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroesopha... | bad-data | |
| Trial is outside EEC, and reported results | 2012-001157-97 | A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Multiple Doses of Esomeprazole Magnesium in a Pediatric Population of 1 to 11 Year olds with Gastroesophageal Reflux Disease (GERD) o... | bad-data | |
| Trial is outside EEC, and reported results | 2012-001158-25 | A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Esomeprazole Magnesium 20 mg and 40 mg in a Pediatric Population of 12 to 17 Year-Olds with Gastroesopha... | bad-data | |
| Trial is outside EEC, and reported results | 2012-001159-37 | A Single-Blind, Randomised, Parallel-Group, Single-Centre Pharmacokinetic and pH-Monitoring Study of Esomeprazole in Infants up to 24 Months of Age | bad-data | |
| Trial is outside EEC, and reported results | 2012-001160-29 | An Open Single-centre Study on the Pharmacokinetics and Pharmacodynamics of Esomeprazole After Once Daily Oral Administration for 7 Days in Preterm Infants and Neonates | bad-data | |
| Trial is outside EEC | 2012-001180-77 | An open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious ... | bad-data | |
| Reported results Terminated | 2012-001869-33 | A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safet... | 2014-06-23 | due-trials |
| Exempt, with results | 2012-002206-52 | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors | 2020-02-28 | not-yet-due |
| Other | 2012-002896-32 | A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support predi... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2012-002900-42 | A randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over, single-dose phase IIa study to investigate the bronchodilatory and systemic effects of 4 different doses of i... | bad-data | |
| Reported results | 2012-003101-10 | A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Or... | 2015-11-03 | due-trials |
| Listed as ongoing, but also has a completion date | 2012-003524-21 | A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma | 2017-01-11 | bad-data |
| Reported results | 2012-003622-25 | A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placeb... | 2022-10-31 | due-trials |
| Reported results | 2012-003895-38 | A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA). [S... | 2016-03-02 | due-trials |
| Reported results | 2012-004006-96 | A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the... | 2016-10-19 | due-trials |
| Reported results | 2012-004098-26 | A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy St... | 2016-12-14 | due-trials |
| Reported results | 2012-004619-30 | A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults with Systemic Lupus Erythematosus | 2018-07-19 | due-trials |
| Exempt | 2012-004628-39 | A Phase I/II, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Ca... | 2023-12-13 | not-yet-due |
| Reported results | 2013-000239-28 | DECLARE Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of ... | 2018-09-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000422-58 | A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA?) 300 mg in Patients with Papillary or Poorly Differentiated Thyr... | 2022-01-10 | bad-data |
| Reported results | 2013-000423-14 | A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differe... | 2019-03-06 | due-trials |
| Reported results | 2013-000788-98 | A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females with Polycystic Ovary Syn... | 2014-07-25 | due-trials |
| Ongoing | 2013-001211-75 | A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete ... | not-yet-due | |
| Other | 2013-001551-13 | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following Fir... | not-yet-due | |
| Ongoing | 2013-001676-38 | A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receivi... | not-yet-due | |
| Trial is outside EEC, and reported results | 2013-001900-13 | A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Ant... | bad-data | |
| Reported results | 2013-002163-26 | A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequatley controll... | 2016-03-11 | due-trials |
| Reported results | 2013-002345-11 | A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting b... | 2016-05-08 | due-trials |
| Reported results Terminated | 2013-002352-32 | A multicentre, randomised, double-blind, paralllel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) added to medium dose inhaled corticosteroid plus long acting ... | 2014-07-25 | due-trials |
| Reported results | 2013-002523-42 | A multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) to reduce oral corticosteroid use in patients with uncontrolle... | 2016-07-06 | due-trials |
| Reported results | 2013-003269-33 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma | 2017-03-01 | due-trials |
| Reported results | 2013-003519-23 | A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in ... | 2019-01-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003520-37 | A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment i... | 2023-08-24 | bad-data |
| Reported results | 2013-003545-41 | A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Th... | 2016-10-26 | due-trials |
| Other | 2013-003839-30 | A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline... | not-yet-due | |
| Reported results | 2013-003935-32 | A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ? 6 Months to < 18 Years Receiving Treatment with Opioids Ensayo fase I, ... | 2021-12-13 | due-trials |
| Not reported | 2013-004319-33 | A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-... | 2014-11-20 | due-trials |
| Reported results | 2013-004473-28 | A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) T... | 2018-02-12 | due-trials |
| Reported results | 2013-004474-96 | A 52-week, double-blind, randomised, multi-centre, parallel-group,Phase III study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort® (budesonide/formoterol) T... | 2017-08-02 | due-trials |
| Reported results | 2013-004579-11 | A Randomised, Double-blind, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 3 Doses of Benralizumab (MED... | 2018-04-09 | due-trials |
| Reported results | 2013-004590-27 | Randomised, double-blind, 56 week placebo-controlled, parallel group, multicentre, phase 3 study to evaluate the efficacy and safety of 2 doses of benralizumab in patients with moderate to very severe... | 2018-04-10 | due-trials |
| Reported results | 2013-004674-97 | A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 ... | 2017-08-25 | due-trials |
| Ongoing | 2013-005137-20 | A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician?s Choice Chemotherapy in the Treatment of Metastatic Brea... | not-yet-due | |
| Reported results | 2013-005293-22 | A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 ... | 2016-04-15 | due-trials |
| Ongoing | 2013-005427-16 | A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at ... | not-yet-due | |
| Reported results | 2013-005614-35 | A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequate... | 2017-07-28 | due-trials |
| Reported results | 2013-005615-27 | A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequate... | 2017-09-21 | due-trials |
| Reported results | 2014-000253-36 | A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders... | 2020-11-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-000336-42 | A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cance... | 2023-08-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-000338-46 | A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) W... | 2023-08-30 | bad-data |
| Exempt | 2014-000440-15 | A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | 2014-07-21 | not-yet-due |
| Ongoing | 2014-000531-17 | A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with EGFRm+/T790M+, Locally Advanced or Metastatic NSCLC who have Progressed Following Prior Therapy w... | not-yet-due | |
| Reported results | 2014-000593-19 | A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 µg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler... | 2016-02-10 | due-trials |
| Ongoing | 2014-000594-39 | A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed... | not-yet-due | |
| Reported results | 2014-000770-19 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialys... | 2018-10-04 | due-trials |
| Reported results | 2014-000780-40 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients | 2018-09-26 | due-trials |
| Reported results | 2014-000972-24 | A Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) | 2015-07-02 | due-trials |
| Reported results | 2014-001006-18 | Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled ... | 2017-02-27 | due-trials |
| Completed, but no date, and reported results | 2014-001053-16 | A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Maint... | bad-data | |
| Reported results | 2014-001069-28 | A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH) | 2020-05-27 | due-trials |
| Reported results | 2014-001086-27 | A Multicenter, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI- 563) in Asthmatic Adults and Adolescents on Inhal... | 2018-07-02 | due-trials |
| Reported results | 2014-001097-34 | A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in... | 2018-10-02 | due-trials |
| Reported results | 2014-001102-17 | A 26-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 26-week Long -term Extension Period to Evaluate the Efficacy and Safety ... | 2016-10-26 | due-trials |
| Reported results | 2014-001391-54 | A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolesc... | 2017-09-07 | due-trials |
| Reported results | 2014-001457-16 | A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M... | 2015-11-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001589-85 | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progr... | 2023-01-27 | bad-data |
| Reported results | 2014-001858-41 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | 2020-04-20 | due-trials |
| Ongoing | 2014-002117-28 | An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma Estudio de fase II abierto sobre ACP-196 en sujetos con linfoma de células del manto | not-yet-due | |
| Reported results | 2014-002601-38 | A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer's Disease (The... | 2018-10-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2014-002694-11 | A phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as first-line treatment in... | 2019-08-06 | bad-data |
| Exempt | 2014-003212-36 | An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia | not-yet-due | |
| Reported results | 2014-003233-26 | A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia | 2019-04-29 | due-trials |
| Reported results | 2014-003242-28 | A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronida... | 2017-06-01 | due-trials |
| Reported results | 2014-003243-34 | Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis | 2017-12-30 | due-trials |
| Reported results | 2014-003244-13 | A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from ... | 2017-09-15 | due-trials |
| Reported results | 2014-003295-23 | A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) . | 2020-07-13 | due-trials |
| Trial is outside EEC, and reported results | 2014-003400-70 | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children age 7 years through 18 years | bad-data | |
| Trial is outside EEC, and reported results | 2014-003401-15 | A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children age 2 years through 6 years | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2014-003438-20 | A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Pl... | 2022-07-19 | bad-data |
| Reported results | 2014-003502-33 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine... | 2016-08-29 | due-trials |
| Reported results | 2014-003503-29 | A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study with a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultane... | 2017-12-28 | due-trials |
| Reported results | 2014-003511-11 | A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients with Type 2 Diabetes Mellitus, and to Inve... | 2015-11-19 | due-trials |
| Reported results | 2014-003637-26 | A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® compared to placebo and compared to Fenofibrate on liver Fat content in hypertriglyce... | 2016-05-26 | due-trials |
| Reported results | 2014-003638-26 | A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® and dapagliFlozin on liver Fat contEnt in type 2 diabetiC patienTs; | 2015-12-11 | due-trials |
| Reported results | 2014-003716-36 | A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects with a Hist... | 2017-02-24 | due-trials |
| Reported results | 2014-003717-29 | A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic... | 2020-07-20 | due-trials |
| Reported results | 2014-003721-18 | A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long -term Extension Period to Evaluate the Efficacy and Safety... | 2019-09-18 | due-trials |
| Reported results | 2014-003725-17 | A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis EINE P... | 2016-02-05 | due-trials |
| Reported results | 2014-003863-40 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metas... | 2020-11-13 | due-trials |
| Reported results | 2014-003896-41 | A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome | 2018-08-13 | due-trials |
| Trial is outside EEC, and reported results | 2014-004132-20 | A multicentre, double-blind, randomised, parallel-group, Phase III study to assess efficacy and safety of D9421-C 9 mg versus Mesalazine 3 g in patients with active Crohn’s Disease in Japan | bad-data | |
| Reported results | 2014-004427-40 | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients with Mild to Moderate Persistent Asthma | 2015-10-07 | due-trials |
| Reported results | 2014-004599-49 | A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 ... | 2018-04-18 | due-trials |
| Reported results | 2014-004632-19 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus | 2018-12-06 | due-trials |
| Reported results | 2014-004633-96 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus | 2018-09-18 | due-trials |
| Reported results | 2014-004715-37 | A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD | 2015-11-17 | due-trials |
| Reported results | 2014-004746-99 | An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous ... | 2016-11-17 | due-trials |
| Reported results | 2014-004902-13 | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron ... | 2016-09-29 | due-trials |
| Reported results | 2014-005084-32 | A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo, a... | 2016-11-24 | due-trials |
| Reported results | 2014-005306-37 | A randomized, double-blind, multiple dosing (14 days), placebo-controlled, incomplete block crossover, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once dail... | 2016-02-08 | due-trials |
| Reported results | 2014-005318-50 | A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, EXE... | 2016-07-25 | due-trials |
| Reported results | 2014-005377-36 | An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type 2 d... | 2016-11-29 | due-trials |
| Reported results | 2014-005420-10 | A randomised, double-blind, double-dummy, parallel-group, multicenter, phase IIb study to evaluate the effect of ticagrelor 10 mg and 45 mg bid versus placebo in reducing the number of days with pain ... | 2016-11-16 | due-trials |
| Reported results | 2014-005450-19 | A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 in Adolescents with Mild to Moderate Asthma Otwarte badanie fazy pierwszej w celu oceny farmakokinetyki MEDI9929 u nastolatk... | 2016-05-17 | due-trials |
| Ongoing | 2014-005530-64 | A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia | not-yet-due | |
| Other | 2014-005582-73 | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previous... | not-yet-due | |
| Reported results | 2015-000159-26 | A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients with Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After at Least One Line of Pr... | 2016-12-29 | due-trials |
| Reported results | 2015-000408-24 | A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes | 2021-05-05 | due-trials |
| Reported results | 2015-000595-10 | A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis | 2016-07-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000609-38 | A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to A... | 2018-01-29 | bad-data |
| Ongoing | 2015-000662-65 | A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Po... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2015-000734-30 | An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian... | 2021-12-17 | bad-data |
| Reported results | 2015-000804-24 | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mellit... | 2017-11-07 | due-trials |
| Reported results | 2015-000857-19 | A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Con... | 2017-06-21 | due-trials |
| Reported results | 2015-000886-30 | A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. | 2018-12-13 | due-trials |
| Ongoing | 2015-001279-39 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First... | not-yet-due | |
| Reported results | 2015-001407-31 | Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Sma... | 2019-04-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001442-29 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis | 2021-01-18 | bad-data |
| Ongoing | 2015-001633-24 | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Pat... | not-yet-due | |
| Ongoing | 2015-001663-39 | A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanc... | not-yet-due | |
| Reported results | 2015-001702-33 | A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administe... | 2017-11-10 | due-trials |
| Reported results | 2015-001706-34 | A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa. | 2019-12-04 | due-trials |
| Reported results | 2015-002001-11 | A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma | 2017-06-26 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-002197-21 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patie... | 2019-08-06 | bad-data |
| Exempt | 2015-002228-25 | An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) | not-yet-due | |
| Reported results | 2015-002376-24 | A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin plus Saxagliptin compared wit... | 2017-03-13 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-002525-19 | A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients Wit... | 2020-12-02 | bad-data |
| Completed, but no date, and reported results | 2015-002676-24 | An exploratory Phase II/III, randomized, double-blind, placebo controlled, parallel design study to evaluate the efficacy, safety and pharmacodynamics of dapagliflozin and dapagliflozin in combination... | bad-data | |
| Reported results | 2015-002726-39 | A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdomi... | 2017-10-26 | due-trials |
| Reported results Terminated | 2015-002758-11 | A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults | 2016-11-07 | due-trials |
| Reported results | 2015-002934-32 | A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors | 2023-03-28 | due-trials |
| Exempt, with results | 2015-003320-30 | A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer C... | not-yet-due | |
| Not reported Terminated | 2015-003428-30 | A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer | 2016-03-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003589-10 | A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squa... | 2021-05-21 | bad-data |
| Exempt, with results | 2015-003639-37 | A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma | 2018-07-03 | not-yet-due |
| Exempt, with results | 2015-003715-38 | A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer | 2020-09-17 | not-yet-due |
| Other | 2015-004005-16 | A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2015-004276-29 | A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A ... | 2017-03-16 | bad-data |
| Listed as ongoing, but also has a completion date | 2015-004454-17 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator¿s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapse... | 2018-01-17 | bad-data |
| Reported results | 2015-004825-14 | A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients with Type 2 Diabetes Mellitus and Hea... | 2019-09-23 | due-trials |
| Reported results | 2015-005041-31 | A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patie... | 2020-04-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-005042-66 | A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 ... | 2024-01-03 | bad-data |
| Other | 2015-005220-26 | A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untre... | not-yet-due | |
| Ongoing | 2015-005317-68 | A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | not-yet-due | |
| Reported results | 2015-005396-25 | A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting ?2 Agonist (MELTEMI) Ensayo de extensión de seguridad,... | 2020-06-18 | due-trials |
| Reported results | 2015-005406-11 | A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered with Dapagliflozin 5mg compared to S... | 2017-07-15 | due-trials |
| Reported results | 2015-005444-33 | A 24 week treatment, multicenter, randomized, double blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 mcg/formoterol fumarate 12 mcg f... | 2017-06-08 | due-trials |
| Reported results | 2016-000154-34 | A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®,as an Active Control, on Lung ... | 2017-12-01 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000300-28 | A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc... | 2023-02-15 | bad-data |
| Exempt, with results | 2016-000323-43 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignanc... | 2020-03-17 | not-yet-due |
| Reported results | 2016-000625-39 | A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Er... | 2022-12-21 | due-trials |
| Exempt, with results | 2016-000662-38 | A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors | 2021-10-29 | not-yet-due |
| Reported results | 2016-000977-19 | A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma | 2018-09-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001202-42 | A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | 2023-11-27 | bad-data |
| Listed as ongoing, but also has a completion date | 2016-001203-23 | A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First... | 2022-05-19 | bad-data |
| Reported results | 2016-001677-33 | A Phase 2b Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in ... | 2018-12-06 | due-trials |
| Trial is outside EEC, and reported results | 2016-001717-24 | Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vacc... | bad-data | |
| Reported results | 2016-002094-36 | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, Unco... | 2018-08-01 | due-trials |
| Reported results | 2016-002863-32 | A phase IIa, randomised, multi-centre, double blind, placebo-controlled 3 periods, crossover study to investigate the efficacy, pharmacokinetics, safety and tolerability of inhaled AZD8871 administer... | 2017-08-18 | due-trials |
| Reported results | 2016-002961-79 | DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Either Preserved or Impai... | 2020-03-24 | due-trials |
| Reported results | 2016-003246-93 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in Adu... | 2019-01-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003346-90 | A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Respon... | 2022-02-17 | bad-data |
| Exempt, with results | 2016-003736-21 | A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies | not-yet-due | |
| Exempt | 2016-003737-15 | A Phase 1/2 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocytic... | not-yet-due | |
| Trial is outside EEC, and reported results | 2016-003775-22 | An Open-label, parallel-group, multi-centre, phase I / III study to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once-daily oral administration of 961H 10 mg and D961... | bad-data | |
| Reported results | 2016-003896-24 | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease | 2020-09-28 | due-trials |
| Reported results | 2016-003897-41 | Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction | 2019-07-17 | due-trials |
| Reported results | 2016-003991-27 | MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skele... | 2019-11-04 | due-trials |
| Completed, but no date | 2016-004108-73 | A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or... | bad-data | |
| Ongoing | 2016-004140-10 | A randomised, double-blind, placebo- and active-controlled, parallel-arm, multicentre study to assess efficacy, pharmacokinetics, safety and tolerability of multiple dose levels of abediterol administ... | not-yet-due | |
| Reported results | 2016-004232-37 | A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke a... | 2019-12-13 | due-trials |
| Reported results | 2016-004655-75 | A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate fixed-dose combination relative to Umeclidinium/Vila... | 2018-05-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-005068-33 | An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies | 2022-12-16 | bad-data |
| Other | 2016-005126-11 | A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma Studio Randomizzato, in Aperto, ... | not-yet-due | |
| Reported results | 2017-000626-35 | A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subje... | 2019-07-16 | due-trials |
| Trial is outside EEC, and reported results | 2017-000702-38 | A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-a... | bad-data | |
| Reported results | 2017-000838-64 | A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA) | 2019-11-12 | due-trials |
| Trial is outside EEC, and reported results | 2017-000848-17 | A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to less than 60 Months of Age | bad-data | |
| Trial is outside EEC, and reported results | 2017-000849-50 | A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Ag... | bad-data | |
| Ongoing | 2017-000920-81 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for F... | not-yet-due | |
| Reported results | 2017-001040-35 | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on ... | 2020-10-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-001054-34 | LUCY - Lynparza Breast Cancer Real World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Me... | 2021-10-08 | bad-data |
| Reported results | 2017-001582-25 | A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment ... | 2020-04-08 | due-trials |
| Exempt | 2017-001902-14 | A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2... | 2018-05-23 | not-yet-due |
| Reported results | 2017-002025-38 | A Phase 2, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects wit... | 2018-01-23 | due-trials |
| Other | 2017-002208-28 | An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON). | not-yet-due | |
| Other | 2017-002359-27 | A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients with EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated with Osimertinib Estudio multicéntrico, abierto... | not-yet-due | |
| Ongoing | 2017-002361-22 | A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment... | not-yet-due | |
| Reported results | 2017-002421-38 | A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with S... | 2020-08-13 | due-trials |
| Reported results | 2017-002483-40 | A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compar... | 2019-09-30 | due-trials |
| Reported results | 2017-002690-19 | A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary bypass graftin... | 2021-06-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002767-17 | A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Parti... | 2022-05-04 | bad-data |
| Reported results | 2017-002817-78 | An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Subjects with Type 2 Diabetes Mellitus Tre... | 2018-12-06 | due-trials |
| Ongoing | 2017-002979-26 | A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Muscle ... | not-yet-due | |
| Reported results | 2017-003029-14 | A phase 3b, multicenter, prospective, randomized, double blind, placebocontrolled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE) | 2018-11-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003078-15 | A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma ... | 2020-11-12 | bad-data |
| Reported results | 2017-003079-69 | A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dep... | 2020-09-25 | due-trials |
| Reported results | 2017-003641-14 | A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 Months, with Sickle Cell Disease | 2019-09-03 | due-trials |
| Reported results | 2017-003675-61 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis | 2020-07-31 | due-trials |
| Reported results | 2017-003820-58 | A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 diab... | 2019-03-19 | due-trials |
| Reported results Terminated | 2017-003955-50 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE) | 2018-12-21 | due-trials |
| Ongoing | 2017-004397-34 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanc... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004521-32 | A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction | 2021-01-18 | bad-data |
| Reported results | 2017-004556-27 | A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineli... | 2020-10-15 | due-trials |
| Other | 2017-004632-11 | A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-005081-22 | An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese S... | 2021-04-14 | bad-data |
| Reported results | 2018-000019-26 | A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects with Type 2 Diabetes Mellitus and Renal Impairment | 2019-02-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000170-30 | A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on H... | 2022-03-24 | bad-data |
| Reported results Terminated | 2018-000175-33 | A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium Cyc... | 2020-05-22 | due-trials |
| Trial is outside EEC, and reported results | 2018-000213-20 | An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients with Ref... | bad-data | |
| Exempt | 2018-000764-29 | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-000802-46 | An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure w... | 2022-03-27 | bad-data |
| Other | 2018-000867-10 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Sma... | not-yet-due | |
| Exempt, with results | 2018-001028-21 | A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancr... | 2024-02-07 | not-yet-due |
| Ongoing | 2018-001061-16 | A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of Osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive... | not-yet-due | |
| Reported results | 2018-001220-19 | An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus | 2019-12-22 | due-trials |
| Other | 2018-001331-48 | A Phase 3, Dose-Escalating Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Increasing Doses of Sodium Zirconium Cyclosilicate (SZC) Given Three Times Daily for the ... | not-yet-due | |
| Not reported | 2018-001375-21 | A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Expression... | 2019-09-25 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-001605-93 | A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants wi... | 2023-10-23 | bad-data |
| Reported results | 2018-001704-10 | A Randomized, Double-blind, Two Treatment, Two Period, Chronic dosing (4 weeks), Crossover, Multi-center Pilot study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycop... | 2019-11-12 | due-trials |
| Reported results | 2018-001722-25 | A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871... | 2019-08-07 | due-trials |
| Other | 2018-001811-59 | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durva... | not-yet-due | |
| Other | 2018-001883-48 | Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and... | not-yet-due | |
| Ongoing | 2018-002011-10 | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-re... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002069-21 | A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Cort... | 2020-11-16 | bad-data |
| Other | 2018-002134-20 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002220-16 | A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Canc... | 2023-04-21 | bad-data |
| Completed, but no date | 2018-002294-22 | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage I... | bad-data | |
| Other | 2018-002443-28 | A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002501-53 | A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Sever... | 2022-05-18 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002523-42 | A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy | 2023-06-29 | bad-data |
| Other | 2018-002572-41 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unres... | not-yet-due | |
| Reported results | 2018-002872-42 | A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy A... | 2023-07-03 | due-trials |
| Reported results | 2018-002895-42 | A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with preserve... | 2020-06-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002931-35 | A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Ce... | 2023-07-18 | bad-data |
| Reported results | 2018-002932-26 | A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA... | 2021-04-06 | due-trials |
| Ongoing | 2018-002997-29 | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C... | not-yet-due | |
| Ongoing | 2018-003012-51 | A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed F... | not-yet-due | |
| Ongoing | 2018-003118-42 | Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients ... | not-yet-due | |
| Ongoing | 2018-003355-38 | A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours | not-yet-due | |
| Other | 2018-003391-13 | A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmat... | not-yet-due | |
| Reported results | 2018-003441-42 | An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with ... | 2020-07-09 | due-trials |
| Reported results | 2018-003442-16 | An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with ... | 2020-03-07 | due-trials |
| Ongoing | 2018-003460-30 | A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance... | not-yet-due | |
| Other | 2018-003467-64 | A 24-week Randomised Exploratory Open-Label Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA (Salbutamol) or AntiInf... | not-yet-due | |
| Exempt | 2018-003688-73 | A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemothe... | not-yet-due | |
| Trial is outside EEC, and reported results | 2018-003701-26 | A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age | bad-data | |
| Exempt, with results | 2018-003857-73 | A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refract... | not-yet-due | |
| Ongoing | 2018-003974-29 | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004079-11 | A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia | 2021-11-22 | bad-data |
| Other | 2018-004105-85 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004346-42 | A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab i... | 2023-10-18 | bad-data |
| Reported results | 2018-004588-30 | A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Subcutaneous Tezepelumab in A... | 2020-06-05 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-004687-64 | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed,... | 2024-03-26 | bad-data |
| Other | 2018-004688-30 | A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine... | not-yet-due | |
| Exempt | 2019-000111-84 | An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma Studio di fase 1b/2, in aperto di acalabrutinib in monoterapia o in ass... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-000114-11 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in H... | 2023-03-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000201-69 | A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-ris... | 2023-01-20 | bad-data |
| Other | 2019-000650-61 | A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutatio... | not-yet-due | |
| Exempt, with results Terminated | 2019-000974-44 | A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (CO... | 2022-03-11 | not-yet-due |
| Trial is outside EEC, and reported results | 2019-001259-37 | An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-001363-67 | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructi... | 2024-01-31 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-001402-20 | An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE) | 2023-01-18 | bad-data |
| Other | 2019-001555-40 | A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroe... | not-yet-due | |
| Other | 2019-001573-89 | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | not-yet-due | |
| Other | 2019-001755-39 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 65 Year... | not-yet-due | |
| Other | 2019-001800-39 | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very S... | not-yet-due | |
| Reported results | 2019-001801-26 | A Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol Administered with a Space... | 2020-12-30 | due-trials |
| Other | 2019-001832-77 | A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Gr... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001866-14 | An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE) Studio di estensione a lungo termine in aperto volto a esami... | 2023-09-19 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001924-37 | SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Trea... | 2023-01-31 | bad-data |
| Other | 2019-002039-27 | A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hyp... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-002871-32 | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) | 2023-02-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-003304-12 | A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis | 2022-09-22 | bad-data |
| Other | 2019-003629-78 | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Horm... | not-yet-due | |
| Ongoing | 2019-003706-27 | SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Brea... | not-yet-due | |
| Ongoing | 2019-003777-26 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003791-39 | A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who hav... | 2021-01-19 | bad-data |
| Ongoing | 2019-003969-18 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGF... | not-yet-due | |
| Other | 2019-004112-60 | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without... | not-yet-due | |
| Not reported Terminated | 2019-004190-46 | A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients Aged... | 2020-06-18 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-004336-31 | A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemothera... | 2023-12-05 | bad-data |
| Exempt | 2019-004483-22 | A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan ... | not-yet-due | |
| Other | 2019-004493-26 | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator's Choice Chemotherapy in HER2- Low, Hormone Receptor Positive Breast Cancer Patients whose D... | not-yet-due | |
| Exempt | 2019-004531-22 | A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with... | not-yet-due | |
| Trial is outside EEC, and reported results | 2019-004638-40 | An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma. | bad-data | |
| Ongoing | 2019-004770-25 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head a... | not-yet-due | |
| Reported results | 2019-004862-16 | A Phase 2, MulticEntre, Double-Blind, THree-Arm, Placebo and Active Control Efficacy and SafetY STudy to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction ... | 2022-04-29 | due-trials |
| Other | 2020-000058-89 | A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatmen... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-000138-16 | A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO) | 2023-02-07 | bad-data |
| Reported results Terminated | 2020-000169-17 | A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneous ... | 2023-03-28 | due-trials |
| Reported results Terminated | 2020-000195-38 | A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Remova... | 2021-03-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-000209-10 | A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progress... | 2022-08-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000255-12 | A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus | 2022-03-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000285-42 | A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36–week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe... | 2022-09-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000287-32 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid Studio multinaz... | 2023-10-26 | bad-data |
| Other | 2020-000346-33 | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastati... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-000554-97 | A Phase I, Open-Label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age with Mild, Moderate, or Severe Asthma (TRAILHEAD) I. fázisú, nyílt vizsgálat a tezepel... | 2022-09-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000556-35 | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Sta... | 2023-09-06 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-000571-20 | A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease... | 2023-11-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000612-30 | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative... | 2024-05-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-000664-31 | A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Acute... | 2023-07-05 | bad-data |
| Reported results | 2020-000767-23 | A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia | 2021-07-20 | due-trials |
| Reported results | 2020-000789-40 | A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate-to-severe Asthma | 2023-02-06 | due-trials |
| Completed, report not yet due | 2020-000840-75 | A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflamm... | 2023-11-08 | not-yet-due |
| Reported results | 2020-000931-35 | A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults with Type 2 Diabetes | 2021-06-09 | due-trials |
| Ongoing | 2020-001001-22 | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, ... | not-yet-due | |
| Other | 2020-001079-33 | A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer (SERENA-3) | not-yet-due | |
| Ongoing | 2020-001520-34 | A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter... | not-yet-due | |
| Other | 2020-001521-31 | A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter... | not-yet-due | |
| Other | 2020-001574-29 | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | not-yet-due | |
| Exempt | 2020-001642-18 | A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies | not-yet-due | |
| Reported results | 2020-001644-25 | A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 Étude de phase 2 randomisée évalu... | 2020-11-17 | due-trials |
| Reported results | 2020-002263-54 | A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease | 2022-09-06 | due-trials |
| Other | 2020-002276-12 | SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-P... | not-yet-due | |
| Ongoing, reported early | 2020-002328-35 | A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Spain... | not-yet-due | |
| Ongoing | 2020-002368-30 | A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring ER2 Activatin... | not-yet-due | |
| Other | 2020-002515-21 | "A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age" | not-yet-due | |
| Other | 2020-002529-27 | A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) É... | not-yet-due | |
| Exempt | 2020-002688-77 | A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in... | not-yet-due | |
| Reported results Terminated | 2020-002828-37 | A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose ranging, Multi centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder Twice Daily for Four W... | 2023-07-20 | due-trials |
| Ongoing | 2020-003062-39 | A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis (W... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-003126-23 | A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure... | 2023-09-22 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-003312-27 | Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients with Symptomatic Heart Failure w... | 2024-07-15 | bad-data |
| Reported results | 2020-003797-51 | A Randomised, Double-blind, Placebo-controlled, Dose-response Study of the Efficacy and Safety of MEDI7352 in Subjects with Painful Osteoarthritis of the Knee | 2023-08-16 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-004068-24 | A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With ... | 2024-04-16 | bad-data |
| Other | 2020-004074-21 | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) | not-yet-due | |
| Ongoing | 2020-004091-18 | A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-004101-32 | A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with ... | 2023-06-01 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-004356-16 | A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and ... | 2023-12-08 | bad-data |
| Other | 2020-004529-22 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | not-yet-due | |
| Exempt | 2020-004637-20 | A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6i and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Recept... | not-yet-due | |
| Other | 2020-004719-28 | A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and ... | not-yet-due | |
| Ongoing | 2020-005048-46 | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Br... | not-yet-due | |
| Exempt, with results Terminated | 2020-005106-25 | A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Ha... | 2023-07-24 | not-yet-due |
| Reported results | 2020-005226-28 | A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the... | 2023-02-10 | due-trials |
| Reported results | 2020-005315-44 | A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults | 2022-10-19 | due-trials |
| Other | 2020-005452-38 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfor... | not-yet-due | |
| Ongoing | 2020-005537-32 | A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cance... | not-yet-due | |
| Completed, report not yet due Terminated | 2020-005561-14 | An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic He... | 2024-03-07 | not-yet-due |
| Other | 2020-005607-39 | A Phase III, Multicentre, International Study with a Parallel, Randomised, Double blind, Placebo controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF... | not-yet-due | |
| Ongoing | 2020-005608-20 | A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged = 1 to < 7 Years with Neurofibroma... | not-yet-due | |
| Ongoing | 2020-005620-12 | A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Wh... | not-yet-due | |
| Exempt | 2020-005648-52 | A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neurofi... | not-yet-due | |
| Completed, report not yet due | 2020-005844-47 | A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with H... | 2024-03-28 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2020-005845-18 | A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia Randomizált, párhuz... | 2022-07-15 | bad-data |
| Completed, but no date | 2020-005960-68 | A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid O... | bad-data | |
| Exempt | 2021-000036-57 | A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Pa... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-000085-14 | A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or ... | 2024-02-13 | bad-data |
| Other | 2021-000267-72 | A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (OR... | not-yet-due | |
| Other | 2021-000336-55 | A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally Adva... | not-yet-due | |
| Other | 2021-000546-17 | SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + C... | not-yet-due | |
| Ongoing | 2021-000603-21 | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Canc... | not-yet-due | |
| Other | 2021-000634-33 | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harbori... | not-yet-due | |
| Exempt | 2021-000857-23 | A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Parti... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-000870-27 | A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) | 2024-10-25 | bad-data |
| Completed, reported early | 2021-001644-10 | A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE) | 2023-10-10 | not-yet-due |
| Other | 2021-001722-21 | MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to ... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-001911-96 | A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with C... | 2024-02-07 | bad-data |
| Other | 2021-002026-24 | A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose I... | not-yet-due | |
| Ongoing | 2021-002040-78 | A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tu... | not-yet-due | |
| Reported results | 2021-002530-17 | A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816,... | 2022-08-02 | due-trials |
| Completed, report not yet due | 2021-002570-54 | A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination with Anti-cancer Agents in Patients with Relapsed/Refractory Peripheral T-cell ... | 2024-02-16 | not-yet-due |
| Other | 2021-002862-42 | A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | not-yet-due | |
| Ongoing | 2021-003024-33 | An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation-Positiv... | not-yet-due | |
| Other | 2021-003031-29 | ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment ROSY-D: Estudio m... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-003221-30 | A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 ... | 2023-02-17 | bad-data |
| Other | 2021-003334-36 | A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose I... | not-yet-due | |
| Ongoing | 2021-003338-35 | A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults ... | not-yet-due | |
| Other | 2021-003369-37 | A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2) Estudio de f... | not-yet-due | |
| Exempt, with results | 2021-003410-39 | A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combin... | 2023-07-24 | not-yet-due |
| Ongoing | 2021-003527-14 | An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia | not-yet-due | |
| Exempt | 2021-003569-36 | A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Rela... | not-yet-due | |
| Other | 2021-003771-34 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with S... | not-yet-due | |
| Other | 2021-003797-30 | A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with S... | not-yet-due | |
| Other | 2021-003822-54 | A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compa... | not-yet-due | |
| Other | 2021-003936-10 | MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or S... | not-yet-due | |
| Other | 2021-004135-89 | Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage ... | not-yet-due | |
| Other | 2021-004327-32 | A Phase III, Randomized, Doubleblind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non s... | not-yet-due | |
| Other | 2021-004346-37 | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), ... | not-yet-due | |
| Other | 2021-004606-21 | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-bas... | not-yet-due | |
| Trial is outside EEC | 2021-005075-38 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in H... | bad-data | |
| Other | 2021-005201-27 | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castra... | not-yet-due | |
| Other | 2021-005223-21 | A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-l... | not-yet-due | |
| Ongoing | 2021-005231-22 | A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and ... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-005457-85 | A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose ... | 2024-09-09 | bad-data |
| Listed as ongoing, but also has a completion date | 2021-005484-53 | A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with ... | 2024-04-19 | bad-data |
| Completed, reported early | 2021-006056-13 | Covid-19: Open-Label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 weeks Gestational Age to < 18 years | 2024-04-16 | not-yet-due |
| Exempt | 2021-006227-17 | A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and i... | not-yet-due | |
| Exempt | 2021-006289-19 | A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients... | not-yet-due | |
| Other | 2021-006374-24 | A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplifie... | not-yet-due | |
| Other | 2021-006577-30 | A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Da... | not-yet-due | |
| Other | 2021-006691-17 | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2022-000152-11 | BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters | 2024-07-19 | bad-data |
| Other | 2022-000493-26 | A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Al... | not-yet-due | |
| Other | 2022-000776-19 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with ... | not-yet-due | |
| Other | 2022-001294-31 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | not-yet-due | |
| Completed, report not yet due | 2022-001476-33 | A Randomized, Double-Blind, 12-Week (with an Extension to 52 weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) De... | 2024-03-26 | not-yet-due |
| Ongoing | 2022-001629-65 | A Randomised, Double-blind, Placebo-Controlled, Multi-Center Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-Cirrhotic Non-Alcoholic Steatohepatiti... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2022-002378-95 | A Phase I/III Randomized, Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairm... | 2023-10-27 | bad-data |
| Listed as ongoing, but also has a completion date | 2022-002441-18 | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pu... | 2024-08-16 | bad-data |
| Other | 2022-002680-30 | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer... | not-yet-due | |
| Ongoing | 2022-002840-29 | A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants ... | not-yet-due | |
| Other | 2022-003107-15 | A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infec... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-003286-37 | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Infl... | bad-data |